Abstract

In this study a new N4 Schiff base ligand (SB) was synthesized via condensation reaction of 3,4-diaminobenzophenone with diacetyl monoxime in 1:2 M ratio. Moreover, the synthesization and characterization of its zinc (II) complex was carried out through elemental analysis, FT-IR, H-1 NMR, UV-Vis spectroscopies and molar conductance. Afterwards we scrutinized the above obtained complex to determine its potential anticancer activity against MCF-7 cell line through MTT test, reducing the viable cell numbers to 11 of the control samples after exposure for 72 h. In order to specify its in vitro antioxidant activity, the Zn(II) complex was evaluated, as a radical scavenger, versus 1,1-diphenyl-2-picrylhydrazyl radicals (DPPH center dot). Data obtained from the above assay revealed that Zn(II) complex demonstrated limited (IC50 = 239.5 mgL(-1)) antioxidant activity in comparison with ascorbic acid. For the purpose of investigating the complex-model proteins binding, human serum albumin (HSA) and beta-lactoglobulin (beta-LG), we used biophysical methods and molecular modeling. Experimental results showed that the two systems demonstrated identical interactions (hydrogen bonding and Van der Waals forces). But the beta-LG demonstrated a much firmer binding affinity to Zn(II) complex than HSA (K-b similar to 0.67 (+/- 0.10) x 10(4) M-1 for HSA-Zn complex and 6.45 (+/- 0.15) x 104 M-1 for beta-LG-Zn complex). According to the molecular modeling analysis, the Zn(II) complex develops bonds to the remnants that exist in the subdomain HA of HSA and site A of beta-LG. (C) 2018 Elsevier B.V. All rights reserved.